Off-label uses of Anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Sánchez Cano, Daniel ^a   Callejas Rubio, José Luis ^b   Ruiz Villaverde, Ricardo ^c   Ríos Fernández, Raquel ^b   Ortego Centeno, Norberto ^b  

^a Hospital Santa Ana   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c Dermatology Dept   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PENTOXIFYLLINE; PLACEBO; THALIDOMIDE; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ANTIBODY; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADD ON THERAPY; ANGIONEUROTIC EDEMA; BEHCET DISEASE; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LUNG SARCOIDOSIS; OFF LABEL DRUG USE; PNEUMONIA; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; SARCOIDOSIS; SINUSITIS; URTICARIA; UVEITIS; VISUAL ACUITY; ANIMAL; AUTOIMMUNE DISEASE; DRUG ANTAGONISM; IMMUNOLOGY; INFLAMMATION; METABOLISM; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; BEHCET SYNDROME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNE DISEASES; BEHCET SYNDROME; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; INFLAMMATION; OFF-LABEL USE; POLYETHYLENE GLYCOLS; RECEPTORS, TUMOR NECROSIS FACTOR; SARCOIDOSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 84883159860     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/286857     Document Type: Review

References (123)

1. Kourbeti I. S., Boumpas D. T., Biological therapies of autoimmune diseases. Current Drug Targets: Inflammation and Allergy 2005 4 1 41 46 2-s2.0-17844366890 10.2174/1568010053622812 (Pubitemid 40584852)
2. Atzeni F., Sarzi-Puttini P., Doria A., Iaccarino L., Capsoni F., Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmunity Reviews 2005 4 3 144 152 2-s2.0-16844381697 10.1016/j.autrev.2004.08.004 (Pubitemid 40488743)
3. Graves J. E., Nunley K., Heffernan M. P., Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). Journal of the American Academy of Dermatology 2007 56 1 e55 e79 2-s2.0-33845685405 10.1016/j.jaad.2006.07.019 (Pubitemid 44969298)
4. Karampetsou M. P., Liossis S.-N. C., Sfikakis P. P., TNF- antagonists beyond approved indications: stories of success and prospects for the future. QJM 2010 103 12 917 928 2-s2.0-78649477259 10.1093/qjmed/hcq152
5. William M., Faez S., Papaliodis G. N., Lobo A. M., Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. Journal of Ophthalmic Inflammation and Infection 2012 2 4 231 233 10.1007/s12348-012-0081-y
6. Keystone E. C., Genovese M. C., Klareskog L., Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Annals of the Rheumatic Diseases 2009 68 6 789 796 10.1136/ard.2008.099010
7. Barrie A., Regueiro M., Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflammatory Bowel Diseases 2007 13 11 1424 1429 2-s2.0-36649003354 10.1002/ibd.20196 (Pubitemid 350206857)
8. Langley R. G., Gupta A. K., Cherman A. M., Inniss K. A., Biologic therapeutics in the treatment of psoriasis-part 1: review. Journal of Cutaneous Medicine and Surgery 2007 11 3 99 122 2-s2.0-34548615862 10.2310/7750.2006. 00060a
9. Baumgart D. C., Sandborn W. J., Inflammatory bowel disease: clinical aspects and established and evolving therapies. The Lancet 2007 369 9573 1641 1657 2-s2.0-34248136340 10.1016/S0140-6736(07)60751-X (Pubitemid 46722637)
10. Hatemi G., Silman A., Bang D., EULAR recommendations for the management of Behçet disease. Annals of the Rheumatic Diseases 2008 67 12 1656 1662 10.1136/ard.2007.080432
11. Curigliano V., Giovinale M., Fonnesu C., Efficacy of etanercept in the treatment of a patient with Behçet's disease. Clinical Rheumatology 2008 27 7 933 936 10.1007/s10067-008-0857-5
12. Arida A., Fragiadaki K., Giavri E., Sfikakis P. P., Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Seminars in Arthritis and Rheumatism 2011 41 1 61 70 2-s2.0-79959599276 10.1016/j.semarthrit.2010.09.002
13. Atzeni F., Sarzi-Puttini P., Capsoni F., Mecchia M., Marrazza M. G., Carrabba M., Successful treatment of resistant Behçet's disease with etanercept. Clinical and Experimental Rheumatology 2005 23 5 729 2-s2.0-24944466610 (Pubitemid 41300729)
14. Melikoglu M., Fresko I., Mat C., Ozyazgan Y., Gogus F., Yurdakul S., Hamuryudan V., Yazici H., Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. Journal of Rheumatology 2005 32 1 98 105 2-s2.0-11844283956 (Pubitemid 40092599)
15. Cantarini L., Tinazzi I., Caramaschi P., Bellisai F., Brogna A., Galeazzi M., Safety and efficacy of etanercept in children with juvenile-onset Behçet's disease. International Journal of Immunopathology and Pharmacology 2009 22 2 551 555 2-s2.0-67650433877
16. Alty J. E., Monaghan T. M., Bamford J. M., A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNF blockade. Clinical Neurology and Neurosurgery 2007 109 3 279 281 2-s2.0-33847031338 10.1016/j.clineuro.2006.11.002
17. Sfikakis P. P., Markomichelakis N., Alpsoy E., Assaad-Khalil S., Bodaghi B., Gul A., Ohno S., Pipitone N., Schirmer M., Stanford M., Wechsler B., Zouboulis C., Kaklamanis P., Yazici H., Anti-TNF therapy in the management of Behçet's disease-review and basis for recommendations. Rheumatology 2007 46 5 736 741 2-s2.0-34347212190 10.1093/rheumatology/kem034 (Pubitemid 47061701)
18. Tabbara K. F., Al-Hemidan A. I., Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. American Journal of Ophthalmology 2008 146 6 845 850 2-s2.0-56249116919 10.1016/j.ajo.2008.09.010
19. Tognon S., Graziani G., Marcolongo R., Anti-TNF- therapy in seven patients with Behçet's uveitis: advantages and controversial aspects. Annals of the New York Academy of Sciences 2007 1110 474 484 2-s2.0-35748951621 10.1196/annals.1423.050 (Pubitemid 350043037)
20. Al-Rayes H., Al-Swailem R., Al-Balawi M., Al-Dohayan N., Al-Zaidi S., Tariq M., Safety and efficacy of infliximab therapy in active Behçet's uveitis: an open-label trial. Rheumatology International 2008 29 1 53 57 2-s2.0-53149090156 10.1007/s00296-008-0606-8
21. Naganuma M., Sakuraba A., Hisamatsu T., Ochiai H., Hasegawa H., Ogata H., Iwao Y., Hibi T., Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflammatory Bowel Diseases 2008 14 9 1259 1264 2-s2.0-54349092816 10.1002/ibd.20457
22. Sari I., Birlik M., Gonen C., Akar S., Gurel D., Onen F., Akkoc N., Cytomegalovirus colitis in a patient with Behçet's disease receiving tumor necrosis factor alpha inhibitory treatment. World Journal of Gastroenterology 2008 14 18 2912 2914 2-s2.0-48049110733 10.3748/wjg.14.2912
23. Keino H., Okada A. A., Watanabe T., Taki W., Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behçet's disease on infliximab therapy. British Journal of Ophthalmology 2011 95 9 1245 1250 2-s2.0-80052132365 10.1136/bjo.2010.194464
24. Markomichelakis N., Delicha E., Masselos S., Fragiadaki K., Kaklamanis P., Sfikakis P. P., A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study. Rheumatology 2011 50 3 593 597 2-s2.0-79952016227 10.1093/rheumatology/keq366
25. Cantini F., Niccoli L., Nannini C., Kaloudi O., Cassarà E., Susini M., Lenzetti I., Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics: Targets and Therapy 2012 6 5 12 2-s2.0-84856726561
26. Markomichelakis N., Delicha E., Masselos S., Sfikakis P. P., Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients. American Journal of Ophthalmology 2012 154 3 534 541 10.1016/j.ajo.2012.03.035
27. Yamada Y., Sugita S., Tanaka H., Kamoi K., Takase H., Mochizuki M., Timing of recurrent uveitis in patients with Behçet's disease receiving infliximab treatment. British Journal of Ophthalmology 2011 95 2 205 208 2-s2.0-79251468764 10.1136/bjo.2009.168856
28. Coulter I., Huda S., Baborie A., Jacob A., Longitudinally extensive transverse myelitis as the sole presentation of neuro-Behçet's disease responding to infliximab. Journal of Spinal Cord Medicine 2012 35 2 122 124 2-s2.0-84858994470 10.1179/2045772311Y.0000000050
29. Adler S., Baumgartner I., Villiger P. M., Behçet's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis. Arthritis Care and Research 2012 64 4 607 611 2-s2.0-84859755879 10.1002/acr.21557
30. Schreiber B. E., Noor N., Juli C. F., Haskard D. O., Resolution of Behçet's syndrome associated pulmonary arterial aneurysms with infliximab. Seminars in Arthritis and Rheumatism 2011 41 3 482 487 2-s2.0-82955233899 10.1016/j.semarthrit.2011.02.006
31. Iwata S., Saito K., Yamaoka K., Tsujimura S., Nawata M., Suzuki K., Tanaka Y., Effects of anti-TNF- antibody infliximab in refractory entero-Behçet's disease. Rheumatology 2009 48 8 1012 1013 2-s2.0-70149102027 10.1093/rheumatology/kep126
32. Kikuchi H., Aramaki K., Hirohata S., Effect of infliximab in progressive Neuro-Behçet's syndrome. Journal of the Neurological Sciences 2008 272 1-2 99 105 2-s2.0-48349083688 10.1016/j.jns.2008.05.002
33. Sakai T., Watanabe H., Kuroyanagi K., Akiyama G., Okano K., Kohno H., Tsuneoka H., Health- and vision-related quality of life in patients receiving infliximab therapy for Behçet uveitis. The British Journal of Ophthalmology 2013 97 3 338 342 10.1136/bjophthalmol-2012-302515
34. Mushtaq B., Saeed T., Situnayake R. D., Murray P. I., Adalimumab for sight-threatening uveitis in Behçet's disease. Eye 2007 21 6 824 825 2-s2.0-34250366261 10.1038/sj.eye.6702352 (Pubitemid 46909189)
35. van Laar J. A. M., Missotten T., van Daele P. L. A., Jamnitski A., Baarsma G. S., van Hagen P. M., Adalimumab: a new modality for Behçet's disease? Annals of the Rheumatic Diseases 2007 66 4 565 566 2-s2.0-34147211262 10.1136/ard.2006.064279 (Pubitemid 46580490)
36. Olivieri I., Leccese P., D'Angelo S., Padula A., Nigro A., Palazzi C., Coniglio G., Latanza L., Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab. Clinical and Experimental Rheumatology 2011 29 4, supplement 67 S54 S57 2-s2.0-80855144525
37. Perra D., Alba M. A., Callejas J. L., Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology 2012 51 10 1825 1831
38. Calvo Catala J., Campos Fernández C., Rueda Cid A., González-Cruz Cervellera M. I., Baixauli Rubio A., Pastor Cubillo M. D., Efficacy of adalimumab in Behçet's disease. Description of 6 cases. Reumatologia Clinica 2011 7 4 258 261
39. Lee S.-W., Lee S.-Y., Kim K.-N., Jung J.-K., Chung W.-T., Adalimumab treatment for life threatening pulmonary artery aneurysm in Behçet disease: a case report. Clinical Rheumatology 2010 29 1 91 93 2-s2.0-72949107812 10.1007/s10067-009-1272-2
40. de Cassan C., de Vroey B., Dussault C., Hachulla E., Buche S., Colombel J.-F., Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease. Journal of Crohn's and Colitis 2011 5 4 364 368 2-s2.0-79958862562 10.1016/j.crohns.2011.03.006
41. Kerns M. J. J., Graves J. E., Smith D. I., Heffernan M. P., Off-label uses of biologic agents in dermatology: a 2006 update. Seminars in Cutaneous Medicine and Surgery 2006 25 4 226 240 2-s2.0-33845422588 10.1016/j.sder.2006. 08.006 (Pubitemid 44894975)
42. Theodossiadis P. G., Markomichelakis N. N., Sfikakis P. P., Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 2007 27 4 399 413 2-s2.0-34247209156 10.1097/MAJ.0b013e3180318fbc (Pubitemid 46624278)
43. Denys B. G., Bogaerts Y., Coenegrachts K. L., de Vriese A. S., Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer? Clinical Science 2007 112 5 281 289 10.1042/CS20060094 (Pubitemid 46392115)
44. Kobylecki C., Shaunak S., Refractory neurosarcoidosis responsive to infliximab. Practical Neurology 2007 7 2 112 115 2-s2.0-34147222766 (Pubitemid 46578851)
45. Uthman I., Touma Z., Khoury M., Cardiac sarcoidosis responding to monotherapy with infliximab. Clinical Rheumatology 2007 26 11 2001 2003 2-s2.0-34948841526 10.1007/s10067-007-0614-1 (Pubitemid 47516998)
46. Salama B., Gicquel J.-J., Lenoble P., Dighiero P. L., Optic neuropathy in refractory neurosarcoidosis treated with TNF- antagonist. Canadian Journal of Ophthalmology 2006 41 6 766 768 2-s2.0-33846289575 10.1139/I06-074 (Pubitemid 46113034)
47. Saleh S., Ghodsian S., Yakimova V., Henderson J., Sharma O. P., Effectiveness of infliximab in treating selected patients with sarcoidosis. Respiratory Medicine 2006 100 11 2053 2059 2-s2.0-33749488305 10.1016/j.rmed.2006.02.017 (Pubitemid 44514944)
48. Barnabe C., McMeekin J., Howarth A., Martin L., Successful treatment of cardiac sarcoidosis with infliximab. Journal of Rheumatology 2008 35 8 1686 1688 2-s2.0-49049089329
49. Santos E., Shaunak S., Renowden S., Scolding N. J., Treatment of refractory neurosarcoidosis with Infliximab. Journal of Neurology, Neurosurgery and Psychiatry 2010 81 3 241 246 2-s2.0-77649171185 10.1136/jnnp.2008.149989
50. Sodhi M., Pearson K., White E. S., Culver D. A., Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respiratory Medicine 2009 103 2 268 273 2-s2.0-58249087010 10.1016/j.rmed.2008. 08.016
51. Garg S., Garg K., Altaf M., Magaldi J. A., Refractory vertebral sarcoidosis responding to infliximab. Journal of Clinical Rheumatology 2008 14 4 238 240 2-s2.0-58149264706 10.1097/RHU.0b013e318181b45a
52. Migliore A., Signore A., Capuano A., Bizzi E., Massafra U., Vacca F., Todino V., Chianelli M., Relevance of 99mTc-HYNIC-tir-octreotide scintigraphy in a patient affected by sarcoidosis with lung and joints involvement and secondary Sjogren's syndrome treated with infliximab: case report. European Review for Medical and Pharmacological Sciences 2008 12 2 127 130 2-s2.0-45149089146 (Pubitemid 351833270)
53. Lim L. L., Fraunfelder F. W., Rosenbaum J. T., Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis and Rheumatism 2007 56 10 3248 3252 2-s2.0-35348914933 10.1002/art.22918 (Pubitemid 47585419)
54. Kumar G., Kang C. A., Giannini C., Neurosarcoidosis presenting as a cerebellar mass. Journal of General Internal Medicine 2007 22 9 1373 1376 2-s2.0-34547842319 10.1007/s11606-007-0272-7 (Pubitemid 47247306)
55. Petropoulos I. K., Vaudaux J. D., Guex-Crosier Y., Anti-TNF- therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital. Klinische Monatsblatter fur Augenheilkunde 2008 225 5 457 461 2-s2.0-47649109914 10.1055/s-2008-1027361 (Pubitemid 352016484)
56. Callejas-Rubio J. L., López-Pérez L., Ortego-Centeno N., Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis. Therapeutics and Clinical Risk Management 2008 4 6 1305 1313 2-s2.0-61549122750
57. Pereira J., Anderson N. E., Mcauley D., Bergin P., Kilfoyle D., Fink J., Medically refractory neurosarcoidosis treated with infliximab. Internal Medicine Journal 2011 41 4 354 357 2-s2.0-79954986581 10.1111/j.1445-5994.2011.02457.x
58. Mehta B., Efthimiou P., Radiographic improvement in sarcoid arthropathy after infliximab treatment. Journal of Rheumatology 2012 39 3 664 665 2-s2.0-84857867080 10.3899/jrheum.111002
59. Hasni S. A., Kunz D., Finzel K., Gruber B. L., Osseous sarcoidosis treated with tumor necrosis factor-inhibitors: case report and review of the literature. Spine 2010 35 18 E904 E907 2-s2.0-77955970044 10.1097/BRS. 0b013e3181dc9a54
60. Loza M. J., Brodmerkel C., Du Bois R. M., Judson M. A., Costabel U., Drent M., Kavuru M., Flavin S., Lo K. H., Barnathan E. S., Baughman R. P., Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis. Clinical and Vaccine Immunology 2011 18 6 931 939 2-s2.0-79957987361 10.1128/CVI.00337-10
61. Stagaki E., Mountford W. K., Lackland D. T., Judson M. A., The treatment of lupus pernio results of 116 treatment courses in 54 patients. Chest 2009 135 2 468 476 2-s2.0-60249097515 10.1378/chest.08-1347
62. Ørum M., Hilberg O., Krag S., Bendstrup E., Beneficial effect of infliximab on refractory sarcoidosis. Danish Medical Journal 2012 59 12 A4535
63. Hostettler K. E., Studler U., Tamm M., Brutsche M. H., Long-term treatment with infliximab in patients with sarcoidosis. Respiration 2012 83 3 218 224 2-s2.0-84857370733 10.1159/000328738
64. Russell E., Luk F., Manocha S., Ho T., O'Connor C., Hussain H., Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy. Seminars in Arthritis and Rheumatism 2013 10.1016/j.semarthrit.2012.10.008
65. Utz J. P., Limper A. H., Kalra S., Specks U., Scott J. P., Vuk-Pavlovic Z., Schroeder D. R., Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003 124 1 177 185 2-s2.0-0038498467 10.1378/chest.124.1.177 (Pubitemid 36851350)
66. Baughman R. P., Lower E. E., Bradley D. A., Raymond L. A., Kaufman A., Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005 128 2 1062 1067 2-s2.0-23744473408 10.1378/chest.128.2.1062 (Pubitemid 41140552)
67. Knopf A., Lahmer T., Chaker A., Stark T., Hofauer B., Pickhard A., Thürmel K., Bas M., Head and neck sarcoidosis, from wait and see to tumor necrosis factor alpha therapy: a pilot study. Head & Neck 2013 35 5 715 719 10.1002/hed.23022
68. Wanat K. A., Rosenbach M., Case series demonstrating improvement in chronic cutaneous sarcoidosis following treatment with TNF inhibitors. Archives of Dermatology 2012 148 9 1097 1100
69. Kaiser C. A., Cozzio A., Hofbauer G. F. L., Kamarashev J., French L. E., Navarini A. A., Disfiguring annular sarcoidosis improved by adalimumab. Case Reports in Dermatology 2011 3 2 103 106 2-s2.0-80052698838 10.1159/000328796
70. Field S., Regan A. O., Sheahan K., Collins P., Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clinical and Experimental Dermatology 2010 35 7 795 796 2-s2.0-77956698536 10.1111/j.1365-2230.2010.03829.x
71. Baughman R. P., Lower E. E., Ingledue R., Kaufman A. H., Management of ocular sarcoidosis. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases 2012 29 1 26 33
72. Patel S. R., Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report. Journal of Medical Case Reports 2009 3 article 8573 2-s2.0-72449207653 10.4076/1752-1947-3-8573
73. Lahmer T., Knopf A., Lanzl I., Heemann U., Thuermel K., Using TNF-alpha antagonist Adalimumab for treatment for multisystem sarcoidosis: a case study. Rheumatology International 2012 32 8 2367 2370 2-s2.0-79957840897 10.1007/s00296-011-1968-x
74. Pariser R. J., Paul J., Hirano S., Torosky C., Smith M., A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. Journal of the American Academy of Dermatology 2013 68 5 765 773 10.1016/j.jaad.2012.10.056
75. Erckens R. J., Mostard R. L. M., Wijnen P. A. H. M., Schouten J. S., Drent M., Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefe's Archive for Clinical and Experimental Ophthalmology 2012 250 5 713 720 2-s2.0-81855224882 10.1007/s00417-011-1844-0
76. Toussirot É., Pertuiset É., Kantelip B., Wendling D., Sarcoidosis occuring during anti-TNF- treatment for inflammatory rheumatic diseases: report of two cases. Clinical and Experimental Rheumatology 2008 26 3 471 475 2-s2.0-48949117129 (Pubitemid 352003220)
77. Sturfelt G., Christensson B., Bynke G., Saxne T., Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab. Journal of Rheumatology 2007 34 11 2313 2314 2-s2.0-35948987607 (Pubitemid 350076897)
78. Vandevyvere K., Luyten F. P., Verschueren P., Lories R., Segaert S., Westhovens R., Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Clinical Rheumatology 2007 26 12 2205 2206 2-s2.0-36249008568 10.1007/s10067-007-0733-8 (Pubitemid 350120373)
79. Almodóvar R., Izquierdo M., Zarco P., Javier Quiroós F., Mazzucchelli R., Steen B., Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clinical and Experimental Rheumatology 2007 25 1 99 101 2-s2.0-33947586414 (Pubitemid 46477494)
80. Metyas S., Arkfeld D. G., Forrester D. M., Ehresmann G. R., Infliximab treatment of familial Mediterranean fever and its effect on secondary AA amyloidosis. Journal of Clinical Rheumatology 2004 10 3 134 137 2-s2.0-3042592556 10.1097/01.rhu.0000128856.13595.eb (Pubitemid 38821988)
81. Daïen C. I., Monnier A., Claudepierre P., Constantin A., Eschard J.-P., Houvenagel E., Samimi M., Pavy S., Pertuiset E., Toussirot E., Combe B., Morel J., Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology 2009 48 8 883 886 2-s2.0-70149125210 10.1093/rheumatology/kep046
82. Samimi M., Lorette G., Machet L., de Muret A., Watier H., Maruani A., Facial granulomatous nodules during etanercept treatment for psoriasis. International Journal of Dermatology 2009 48 9 1025 1027 2-s2.0-69249139917 10.1111/j.1365-4632.2009.04080.x
83. Pink A. E., Fonia A., Smith C. H., Barker J. N. W. N., The development of sarcoidosis on antitumour necrosis factor therapy: a paradox. British Journal of Dermatology 2010 163 3 648 649 2-s2.0-77955878472 10.1111/j.1365-2133.2010. 09843.x
84. Clementine R. R., Lyman J., Zakem J., Mallepalli J., Lindsey S., Quinet R., Tumor necrosis factor-alpha antagonist-induced sarcoidosis. Journal of Clinical Rheumatology 2010 16 6 274 279 2-s2.0-77956447699 10.1097/RHU. 0b013e3181efa190
85. Tong D., Manolios N., Howe G., Spencer D., New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication. Internal Medicine Journal 2012 42 1 89 94 2-s2.0-84856292278 10.1111/j.1445-5994.2011.02612.x
86. Salvatierra J., Magro-Checa C., Rosales-Alexander J. L., Raya-Alvarez E., Acute sarcoidosis as parotid fever in rheumatoid arthritis under anti-tumor necrosis factor- therapy. Rheumatology 2011 50 7 1346 1348 2-s2.0-79959475048 10.1093/rheumatology/ker166
87. Marcella S., Welsh B., Foley P., Development of sarcoidosis during adalimumab therapy for chronic plaque psoriasis. Australasian Journal of Dermatology 2011 52 3 e8 e11 2-s2.0-80051758314 10.1111/j.1440-0960.2010.00660.x
88. Bhamra K., Stevens R., Pulmonary sarcoidosis following etanercept treatment. Case Reports in Rheumatology 2012 2012 4 724013 10.1155/2012/724013
89. Lamrock E., Brown P., Development of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonists. Australasian Journal of Dermatology 2012 53 4 e87 e90 2-s2.0-84856863662 10.1111/j.1440-0960.2011. 00863.x
90. Burns A. M., Green P. J., Pasternak S., Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab. Journal of Cutaneous Pathology 2012 39 2 289 293 2-s2.0-84859270666 10.1111/j.1600-0560. 2011.01795.x
91. van der Stoep D., Braunstahl G.-J., van Zeben J., Wouters J., Sarcoidosis during anti-tumor necrosis factor- therapy: no relapse after rechallenge. Journal of Rheumatology 2009 36 12 2847 2848 2-s2.0-72449122946 10.3899/jrheum.090307
92. Palucka A. K., Blanck J.-P., Bennett L., Pascual V., Banchereau J., Cross-regulation of TNF and IFN- in autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America 2005 102 9 3372 3377 2-s2.0-14744276518 10.1073/pnas.0408506102 (Pubitemid 40328052)
93. Mavragani C. P., Niewold T. B., Moutsopoulos N. M., Pillemer S. R., Wahl S. M., Crow M. K., Augmented interferon- pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis and Rheumatism 2007 56 12 3995 4004 2-s2.0-37149024418 10.1002/art.23062 (Pubitemid 350262327)
94. Ioannou Y., Isenberg D. A., Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis & Rheumatism 2000 43 7 1431 1442 (Pubitemid 30452458)
95. Fleisher L. N., Ferrell J. B., McGahan M. C., Ocular inflammatory effects of intravitreally injected tumor necrosis factor-alpha and endotoxin. Inflammation 1990 14 3 325 335 2-s2.0-0025327539 10.1007/BF00915816 (Pubitemid 20174282)
96. Rosenbaum J. T., Howes E. L. Jr., Rubin R. M., Samples J. R., Ocular inflammatory effects of intravitreally-injected tumor necrosis factor. American Journal of Pathology 1988 133 1 47 53 2-s2.0-0023684726
97. de Vos A. F., Van Haren M. C., Verhagen C., Hoekzema R., Kijlstra A., Tumour necrosis factor-induced uveitis in the Lewis rat is associated with intraocular interleukin 6 production. Experimental Eye Research 1995 60 2 199 207 2-s2.0-0028873427 10.1016/S0014-4835(95)80011-5
98. Wang Y., Gaudio P. A., Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome. Ocular Immunology and Inflammation 2008 16 4 167 171 2-s2.0-50049097566 10.1080/09273940802204527
99. Ally M. R., Veerappan G. R., Koff J. M., Treatment of recurrent Crohn's uveitis with infliximab. American Journal of Gastroenterology 2008 103 8 2150 2151 2-s2.0-49349093828 10.1111/j.1572-0241.2008.01982-12.x
100. Tugal-Tutkun I., Ayranci Ö., Kasapcopur Ö., Kir N., Retrospective analysis of children with uveitis treated with infliximab. Journal of AAPOS 2008 12 6 611 613 2-s2.0-57649221987 10.1016/j.jaapos.2008.08.007
101. Kahn P., Weiss M., Imundo L. F., Levy D. M., Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006 113 5 860 864 2-s2.0-33646163230 10.1016/j.ophtha.2006.01.005
102. Fukuda K., Kumagai N., Nakamura H., Kubo M., Matsuzaki M., Nishida T., Successful treatment of cystoid macular edema with etanercept in a patient with rheumatoid arthritis associated panuveitis. Nippon Ganka Gakkai Zasshi 2008 112 1 51 57 2-s2.0-41449101029
103. Kinouchi R., Hirokawa H., Igarashi S., Fukui K., Hirano Y., Takai Y., Yoshida A., A case of panuveitis with optic disc neovascularization associated with juvenile idiopathic arthritis which progressed during a clinical trial of etanercept. Nippon Ganka Gakkai Zasshi 2007 111 12 970 975 2-s2.0-40349091728
104. di Gangi M., Foti R., Leonardi R., Leonetti C., Castellino P., Recurrent new-onset uveitis in a patient with rheumatoid arthritis during anti-TNF treatment. Reumatismo 2007 59 2 169 172 2-s2.0-35449005287
105. Lopez-Gonzalez R., Loza E., Jover J. A., Benitez Del Castillo J. M., Mendez R., Hernandez-Garcia C., Pato E., Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study. Scandinavian Journal of Rheumatology 2009 38 1 58 62 2-s2.0-61649084254 10.1080/03009740802366076
106. Huynh N., Cervantes-Castaneda R. A., Bhat P., Gallagher M. J., Foster C. S., Biologic response modifier therapy for psoriatic ocular inflammatory disease. Ocular Immunology and Inflammation 2008 16 3 89 93 2-s2.0-45749154816 10.1080/09273940802023786 (Pubitemid 351874121)
107. Jolly M., Curran J. J., Infliximab-responsive uveitis and vasculitis in a patient with Takayasu arteritis. Journal of Clinical Rheumatology 2005 11 4 213 215 2-s2.0-23644443535 10.1097/01.rhu.0000173218.28013.3e (Pubitemid 41134332)
108. Braun J., Baraliakos X., Listing J., Sieper J., Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis and Rheumatism 2005 52 8 2447 2451 2-s2.0-23644452510 10.1002/art.21197 (Pubitemid 41117431)
109. Farvardin M., Afarid M., Mehryar M., Hosseini H., Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 2010 30 9 1530 1535 2-s2.0-77958586098 10.1097/IAE.0b013e3181d3758a
110. Vazquez-Cobian L. B., Flynn T., Lehman T. J. A., Adalimumab therapy for childhood uveitis. Journal of Pediatrics 2006 149 4 572 575 2-s2.0-33749131976 10.1016/j.jpeds.2006.04.058 (Pubitemid 44468085)
111. Biester S., Deuter C., Michels H., Haefner R., Kuemmerle-Deschner J., Doycheva D., Zierhut M., Adalimumab in the therapy of uveitis in childhood. British Journal of Ophthalmology 2007 91 3 319 324 2-s2.0-33947581722 10.1136/bjo.2006.103721 (Pubitemid 46586527)
112. Gallagher M., Quinones K., Cervantes-Castañeda R. A., Yilmaz T., Foster C. S., Biological response modifier therapy for refractory childhood uveitis. British Journal of Ophthalmology 2007 91 10 1341 1344 2-s2.0-34848917579 10.1136/bjo.2007.124081 (Pubitemid 47492870)
113. Guignard S., Gossec L., Salliot C., Ruyssen-Witrand A., Luc M., Duclos M., Dougados M., Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Annals of the Rheumatic Diseases 2006 65 12 1631 1634 2-s2.0-33751259674 10.1136/ard.2006.052092 (Pubitemid 44799677)
114. Rudwaleit M., Rødevand E., Holck P., Vanhoof J., Kron M., Kary S., Kupper H., Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Annals of the Rheumatic Diseases 2009 68 5 696 701 2-s2.0-66149093549 10.1136/ard.2008.092585
115. Díaz-Llopis M., García-Delpech S., Salom D., Udaondo P., Hernández-Garfella M., Bosch-Morell F., Quijada A., Romero F. J., Adalimumab therapy for refractory uveitis: a pilot study. Journal of Ocular Pharmacology and Therapeutics 2008 24 3 351 361 2-s2.0-44349084092 10.1089/jop.2007.0104 (Pubitemid 351733224)
116. Sen E. S., Sharma S., Hinchcliffe A., Dick A. D., Ramanan A. V., Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease-a case cohort interventional study. Rheumatology 2012 51 12 2199 2203 10.1093/rheumatology/kes212
117. Díaz-Llopis M., Salom D., Garcia-de-Vicuña C., Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012 119 8 1575 1581
118. Suhler E. B., Lowder C. Y., Goldstein D. A., Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. The British Journal of Ophthalmology 2013 97 4 481 486 10.1136/bjophthalmol-2012- 302292
119. Dobner B. C., Max R., Becker M. D., A three-centre experience with adalimumab for the treatment of non-infectious uveitis. The British Journal of Ophthalmology 2013 97 2 134 138 10.1136/bjophthalmol-2011-301401
120. Magli A., Forte R., Navarro P., Russo G., Orlando F., Latanza L., Alessio M., Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefe's Archive for Clinical and Experimental Ophthalmology 2013 251 6 1601 1606 10.1007/s00417-013-2275-x
121. Zannin M. E., Birolo C., Gerloni V. M., Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. The Journal of Rheumatology 2013 40 1 74 79 10.3899/jrheum.120583
122. Simonini G., Taddio A., Cattalini M., Caputo R., De Libero C., Naviglio S., Bresci C., Lorusso M., Lepore L., Cimaz R., Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care & Research 2011 63 4 612 618 2-s2.0-79957511363
123. Wendling D., Paccou J., Berthelot J.-M., Flipo R.-M., Guillaume-Czitrom S., Prati C., Dernis E., Direz G., Ferrazzi V., Ristori J.-M., New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Seminars in Arthritis and Rheumatism 2011 41 3 503 510 2-s2.0-82955195759 10.1016/j.semarthrit.2011.05.005